Celldex Therapeutics, Inc.
CLDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $730 | $695 | $1,175 |
| % Growth | -100% | 5% | -40.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $819 |
| Gross Profit | $0 | $730 | $695 | $356 |
| % Margin | – | 100% | 100% | 30.3% |
| R&D Expenses | $62,931 | $54,196 | $52,614 | $46,120 |
| G&A Expenses | $10,686 | $10,391 | $10,820 | $10,263 |
| SG&A Expenses | $10,686 | $10,391 | $10,820 | $10,263 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $73,617 | $64,587 | $63,434 | $56,383 |
| Operating Income | -$73,617 | -$63,857 | -$62,739 | -$56,027 |
| % Margin | – | -8,747.5% | -9,027.2% | -4,768.3% |
| Other Income/Exp. Net | $6,573 | $7,257 | $8,943 | $8,935 |
| Pre-Tax Income | -$67,044 | -$56,600 | -$53,796 | -$47,092 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$67,044 | -$56,600 | -$53,796 | -$47,092 |
| % Margin | – | -7,753.4% | -7,740.4% | -4,007.8% |
| EPS | -1.01 | -0.85 | -0.81 | -0.71 |
| % Growth | -18.8% | -4.9% | -14.1% | – |
| EPS Diluted | -1.01 | -0.85 | -0.81 | -0.71 |
| Weighted Avg Shares Out | 66,420 | 66,392 | 66,383 | 66,353 |
| Weighted Avg Shares Out Dil | 66,420 | 66,392 | 66,383 | 66,353 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,573 | $7,257 | $8,943 | $8,935 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $824 | $873 | $867 | $819 |
| EBITDA | -$66,220 | -$62,984 | -$61,872 | -$55,208 |
| % Margin | – | -8,627.9% | -8,902.4% | -4,698.6% |